LONDON, UK – January 20, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for mOm Incubators Ltd (“mOm”) and is pleased to announce the placement of Daniel Green as Chief Operating Officer (COO).
Researchers' expectations of antibodies are changing—from "whether they can be used" to "whether they are stable enough, easy to engineer, and truly meet research needs."
Our strategy sets out to bring deeper mechanistic understanding at the molecular and cellular level to all stages of projects, from Idea to pre-clinical candidate.
In this role, you will define the vision and strategy for CRH early project enablement, establishing robust processes to select and advance promising targets into the drug discovery portfolio. You will lead and develop a matrixed team, guiding them to deliver clear go/nogo decisions through deep expertise in target feasibility and druggability.
This post represents an opportunity to join an exciting multipartner consortium in the ‘END2AMR’ project to help develop novel antimicrobials using high throughput transposon mutagenesis to help understand mechanisms of action, host susceptibility and resistance. The candidate will join the Webber group within the Quadram Institute and have opportunities to develop their skillset within a vibrant and supportive environment.
Creative Biolabs, a USA-based biotechnology company specializing in iPSC research, is delighted to announce its advances in iPSC services.
A fast and powerful way to end firefighting, frustration and friction.
As organisations grow, they also grow in complexity. Teams become busier, priorities multiply, and decision-making gets harder. Leaders feel like they are firefighting symptoms without ever getting to the root cause.
This is the second event in a three-part event series which will help growing ventures understand and develop compliance foundations that investors expect. This session will be held in-person only.
Early-stage companies such as those in life-sciences operate in one of the most opportunity-rich—and heavily scrutinised—sectors in the UK. As they grow, seek investment, partner with strategic corporates, or prepare for acquisition, investors and financing banks will expect credible, proportionate governance foundations that protect and create value, and minimise avoidable risk.